Valsartan-Sacubitril Precipitated Pulmonary ...

Valsartan-Sacubitril Precipitated Pulmonary Edema – A Case Report

Author Name : Dr. Sai Keerthana P C, Midhun M Nair, Sana N, Nesma C H, Dr. Fathimath Shadiya C H

ABSTRACT ARNI (Angiotensin Receptor Neprilysin Inhibitor) is a combination of sacubitril and valsartan that increases the level of natriuretic peptide, which may play an important role in the reduction of pulmonary pressure. Cardiogenic pulmonary edema occurs when there is an issue with the heart’s ability to pump blood effectively, leading to fluid backup in the lungs. Conditions such as congestive heart failure, heart attack, heart valve disorders, and cardiomyopathy can contribute to cardiogenic pulmonary edema. In contrast, non-cardiogenic pulmonary edema is not directly related to heart problems. Instead, it can be caused by factors such as acute respiratory distress syndrome (ARDS), pneumonia, severe infections, inhalation of toxic substances, neardrowning incidents, or certain medications. Here we report a case showing exacerbation of pulmonary edema due to ARNI. Pulmonary edema is a rare but potentially dangerous adverse effect of ARNI. It often presents an abnormal accumulation of extravascular fluid in the lung parenchyma. This process leads to diminished gas exchange at the alveolar level, progressing to potentially causing respiratory failure.